> Detailanzeige

Vinti, Luciana; Pagliara, Daria; Buffardi, Salvatore; Di Ruscio, Valentina; Stocchi, Francesca; Mariggiò, Elena; Parasole, Rosanna; De Matteo, Antonia; Petruzziello, Fara; Paganelli, Valeria; De Vito, Rita; Del Bufalo, Francesca; Strocchio, Luisa; Locatelli, Franco

Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma
  • Beteiligte: Vinti, Luciana; Pagliara, Daria; Buffardi, Salvatore; Di Ruscio, Valentina; Stocchi, Francesca; Mariggiò, Elena; Parasole, Rosanna; De Matteo, Antonia; Petruzziello, Fara; Paganelli, Valeria; De Vito, Rita; Del Bufalo, Francesca; Strocchio, Luisa; Locatelli, Franco
  • Erschienen: Wiley, 2022
  • Erschienen in: Pediatric Blood & Cancer, 69 (2022) 4
  • Sprache: Englisch
  • DOI: 10.1002/pbc.29557
  • ISSN: 1545-5009; 1545-5017
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: AbstractAlthough children and young adults with Hodgkin's lymphoma usually have a favorable prognosis, patients with primary refractory disease and some subsets of relapsed patients still have a dismal outcome. Brentuximab vedotin (BV) in combination with bendamustine may represent a suitable salvage therapy; data on 32 patients aged less than 25 years were retrospectively analyzed. Patients received up to six cycles of treatment of BV 1.8 mg/kg on day 1 and bendamustine 90–120 mg/m2 on days 2 and 3. At the end of treatment, the overall response rate was 81%. The 3‐year overall and progression‐free survivals are 78.1% and 67%, respectively.